Head-To-Head Analysis: ABVC BioPharma (NASDAQ:ABVC) versus Rhythm Pharmaceuticals (NASDAQ:RYTM)

Rhythm Pharmaceuticals (NASDAQ:RYTM) and ABVC BioPharma (NASDAQ:ABVC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, dividends, valuation, earnings, profitability and analyst recommendations.

Insider and Institutional Ownership

11.4% of ABVC BioPharma shares are held by institutional investors. 5.6% of Rhythm Pharmaceuticals shares are held by insiders. Comparatively, 11.9% of ABVC BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Rhythm Pharmaceuticals and ABVC BioPharma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$77.43 million	43.29	-$184.68 million	($4.33)	-12.60
ABVC BioPharma	$150,000.00	46.73	-$10.52 million	($0.86)	-0.63

ABVC BioPharma has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Rhythm Pharmaceuticals has a beta of 2.16, meaning that its share price is 116% more volatile than the S&P 500. Comparatively, ABVC BioPharma has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Rhythm Pharmaceuticals and ABVC BioPharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	0	1	10	0	2.91
ABVC BioPharma	0	0	0	0	0.00

Rhythm Pharmaceuticals presently has a consensus price target of $68.09, suggesting a potential upside of 24.85%. Given Rhythm Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Rhythm Pharmaceuticals is more favorable than ABVC BioPharma.

Profitability

This table compares Rhythm Pharmaceuticals and ABVC BioPharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-230.07%	-367.36%	-77.47%
ABVC BioPharma	-1,619.65%	-104.94%	-56.81%

Summary

ABVC BioPharma beats Rhythm Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

About ABVC BioPharma

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.